Test Detects CMV in Transplant Patients

Share this content:

The FDA has granted premarket approval to a test that assesses a patient's viral load of cytomegalovirus (CMV), the most common and important viral infection in recipients of solid organ transplants.

The fully automated COBAS AmpliPrep/COBAS TaqMan CMV Test, from Roche, is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens.

You must be a registered member of Renal and Urology News to post a comment.